The reasons for VDZ treatment were steroid-dependent colitis in 19 (26.0%), steroid-refractory colitis in 6 (8.2%), failure or intolerance to anti-TNF therapy in 10 (13.7%), and clinician/patient preference in 38 (52.1%) patients. This evidence concerns the gene TNF and colitis.